Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
Published in COVID-19 and
1 other channel

Journal Scan / Research · July 19, 2021

Effects of Specific Type 2 Diabetes Therapies on COVID-19 Outcomes

Diabetes Care

 

 Save  Recommend
 Share

Additional Info

Diabetes Care
Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes
Diabetes Care 2021 Jun 16;[EPub Ahead of Print], AR Kahkoska, TJ Abrahamsen, GC Alexander, TD Bennett, CG Chute, MA Haendel, KR Klein, H Mehta, JD Miller, RA Moffitt, T Stürmer, K Kvist, JB Buse, N3C Consortium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated